|RXII -- USA Stock|| |
USD 1.98 0.06 3.12%
Chief Devel. Officer
Ms. Pamela Pavco, Ph.D. is a Chief Development Officer of RXI Pharmaceuticals Corporationrationration. Prior to this, Dr. Pavco served as our Senior Vice President of Pharmaceutical Development from September 24, 2011 until April 2012. From March 2007 to September 24, 2011, she served as the Vice President of Pharmaceutical Development of Galena Biopharma, Inc. Dr. Pavco has over 20 years of research and development experience in oligonucleotides. Dr. Pavco was Senior Director, Research and Development Project Management at Sirna Therapeutics, Inc., from 2002 until 2006, when it was acquired by Merck Co., Inc. for 1.1 billion. While at Sirna, she was responsible for the discovery research and development of Sirna027, the first chemically modified siRNA to enter clinical trials. Dr. Pavco also managed Sirnas alliance with Allergan, Inc. that was initiated to continue discovery research in the area of ophthalmology and take Sirna027 forward into Phase 2 clinical studies. While at Sirna, Dr. Pavco served in various additional capacities, including Director of Biology Research and Director of Pharmacology and she also managed numerous corporate collaborations and internal programs focusing on the development of therapeutic oligonucleotides in the fields of oncology, antiangiogenesis, hepatitis, respiratory disease and Huntingtons disease. Dr. Pavco has authored numerous scientific articles and contributed to approximately 58 patents and patent applications in the oligonucleotide therapeutics field
Age: 57 Executive Since 2012 Ph.D
Pavco received a Ph.D. in Biochemistry from Virginia Commonwealth University in 1983 and did her postdoctoral work at Duke University. She is a member of the American Association of Cancer Research and the Association for Research and Vision in Ophthalmology.